RICHMOND, British Columbia, Nov. 14, 2005 (PRIMEZONE) -- BioCurex, Inc. (Pink Sheets:BOCX) is pleased to notify its shareholders that an online version of Dr. Moro's presentation to the ISOBM 2005 meeting is available on the company's website.
The presentation begins with a short video showing the Chairman of the Scientific Session calling BioCurex's RECAF a "miracle protein". Dr. Moro then discusses the results that provide significant evidence of the value of RECAF technology in many different types of cancers.
The presentation includes a comparison, cancer by cancer, of the data obtained by BioCurex with data obtained in a blind study by an external independent research group. In one case (benign breast tumors vs. cancer) the results from the blind test were slightly lower than ours but yet very significant, whereas in most other cases, the results obtained with the blind samples were similar or even better than our own -- such as with breast cancers vs. normal individuals, in which the RECAF blind test achieved 100% Sensitivity with 100% Specificity on the 43 cancer and 50 normal samples sent by the independent scientists.
The talk included diagnostic test results on tissue sections and blood samples, as well as preliminary results on the therapeutic applications demonstrating that RECAF technology can be used to kill 100% of cancer cells in culture without killing a significant number of normal cells.
To listen and view the presentation, visit http://www.biocurex.com/media/ISOBM_2005_PRESENTATION
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(tm) Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAF(tm) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.